Opportunity Information: Apply for RFA AG 23 020
Building Infrastructure for Precision Medicine Research on Minority Health and Disparities in Alzheimers Disease (AD) and AD-Related Dementias (ADRD) is a National Institutes of Health (NIH) cooperative agreement funding opportunity (RFA-AG-23-020) designed to jump-start and support collaborative programs that create the practical, research-ready infrastructure needed to do precision medicine studies in Alzheimer-related conditions among populations that have been historically underrepresented in AD/ADRD research. The core idea is not simply to fund another standalone study, but to help teams assemble the foundational resources, partnerships, and integrated datasets that make it possible to conduct more informative, tailored, and equitable research on risk, progression, and outcomes in diverse communities that experience minority health challenges and health disparities.
A central emphasis of the opportunity is building infrastructure that supports precision medicine approaches, meaning the infrastructure should enable researchers to understand how a wide range of factors combine to influence AD/ADRD in different individuals and groups. The announcement highlights the importance of bringing together multiple kinds of data in a coordinated way, including neurobiological information (for example, biomarkers or other brain-related measures), environmental exposures, behavioral factors, and social science data that capture lived experience and structural drivers of health. In practice, the program is meant to catalyze integrated and expanded research that can better reflect real-world diversity, improve scientific validity for understudied groups, and create a platform for innovative future studies that would otherwise be hard to launch without shared resources and coordinated planning.
This is a discretionary health funding opportunity under CFDA 93.866, offered as a cooperative agreement. That structure matters because cooperative agreements typically involve substantial programmatic involvement from NIH compared to a standard grant mechanism, often including coordination expectations, milestone-driven progress, and active collaboration with NIH staff and potentially other awardees. The title also specifies "UH2/UH3" and "Clinical Trial Not Allowed," indicating the work is intended to focus on infrastructure development and related research activities that do not meet NIHs definition of a clinical trial. In other words, applicants should plan around building and strengthening the research ecosystem (data resources, recruitment and retention capabilities, harmonized measures, governance structures, and community-engaged research capacity) rather than proposing an interventional clinical trial.
The opportunity is broad in who can apply, which aligns with the goal of expanding representation and capacity across different settings. Eligible applicants include a wide range of U.S.-based organizations and government entities such as state, county, city or township governments, special district governments, independent school districts, public and state-controlled institutions of higher education, private institutions of higher education, federally recognized Native American tribal governments, public housing authorities/Indian housing authorities, and Native American tribal organizations other than federally recognized tribal governments. It also allows nonprofits (both with and without 501(c)(3) status), for-profit organizations other than small businesses, small businesses, and other entities. The announcement further calls out additional eligible applicant types that are especially relevant to disparity-focused research capacity building, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, regional organizations, eligible federal agencies, tribal governments other than federally recognized ones, and U.S. territories or possessions. This breadth supports partnerships that can connect academic expertise with trusted community presence and culturally grounded engagement.
There are also strict limitations related to foreign involvement. Non-domestic (non-U.S.) entities or foreign institutions are not eligible to apply. Non-domestic components of U.S. organizations are not eligible, and foreign components (as NIH defines them in the NIH Grants Policy Statement) are not allowed. These restrictions mean the project activities and organizational participation must remain domestic under NIH rules, which is important for applicants planning multi-site collaborations or data coordination across borders.
From a practical standpoint, the funding details included with the listing indicate an award ceiling of $350,000, with the original closing date listed as October 21, 2022, and the opportunity created on August 8, 2022. While the listing does not specify the exact number of expected awards in the provided text, the intent is clearly to seed multiple collaborative efforts that collectively strengthen the field's ability to conduct precision medicine research addressing minority health and disparities in AD/ADRD. Overall, the opportunity is best understood as an infrastructure-building push: it aims to help teams create durable resources and collaborative frameworks that make it possible to recruit, characterize, and follow understudied populations with richer, more multidimensional data, ultimately enabling more equitable and more precise Alzheimer and dementia research going forward.Apply for RFA AG 23 020
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Building Infrastructure for Precision Medicine Research on Minority Health and Disparities in Alzheimers Disease (AD) and AD-Related Dementias (ADRD) (UH2/UH3 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.866.
- This funding opportunity was created on 2022-08-08.
- Applicants must submit their applications by 2022-10-21. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $350,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is this funding opportunity?
This opportunity is a National Institutes of Health (NIH) cooperative agreement funding announcement titled Building Infrastructure for Precision Medicine Research on Minority Health and Disparities in Alzheimer's Disease (AD) and AD-Related Dementias (ADRD), identified as RFA-AG-23-020. It is intended to jump-start and support collaborative programs that build practical, research-ready infrastructure for precision medicine studies in AD/ADRD among historically underrepresented populations.
What is the main goal of the program?
The main goal is to create and strengthen the foundational infrastructure needed to conduct more informative, tailored, and equitable AD/ADRD research in diverse communities affected by minority health challenges and health disparities. Rather than funding a single standalone research study, the emphasis is on building the resources, partnerships, and integrated datasets that make future precision medicine research possible.
Is this meant to fund a standalone Alzheimer’s study?
No. The central idea is not to fund another standalone study. The program is designed to help teams assemble infrastructure and coordinated capabilities (such as partnerships, harmonized measures, governance, and integrated data resources) that enable future research on AD/ADRD risk, progression, and outcomes in diverse and historically underrepresented populations.
What does “precision medicine” mean in this context?
Here, precision medicine refers to infrastructure that enables researchers to understand how a broad range of factors combine to influence AD/ADRD in different individuals and groups. The infrastructure should support combining multiple kinds of data so researchers can better reflect real-world diversity and improve scientific validity for understudied groups.
What types of data does the announcement emphasize integrating?
The announcement highlights coordinated integration of multiple data domains, including:
- Neurobiological information (for example, biomarkers or other brain-related measures)
- Environmental exposures
- Behavioral factors
- Social science data capturing lived experience and structural drivers of health
What kinds of infrastructure activities are implied by the description?
Based on the description, infrastructure-building may include developing or strengthening capabilities such as data resources, recruitment and retention capacity, harmonized measures, governance structures, and community-engaged research capacity, with the broader aim of enabling integrated precision medicine research in AD/ADRD disparities.
What funding mechanism is being used?
This is a cooperative agreement funding opportunity. The listing describes it as a discretionary health funding opportunity (CFDA 93.866) offered as a cooperative agreement with the UH2/UH3 structure.
Why does it matter that this is a cooperative agreement?
Cooperative agreements typically involve substantial programmatic involvement from NIH compared with standard grants. As described in the listing, this often includes coordination expectations, milestone-driven progress, and active collaboration with NIH staff and potentially other awardees.
What does “UH2/UH3” indicate?
The announcement specifies a UH2/UH3 cooperative agreement structure. The provided information does not list phase-specific details, but it does indicate the project is organized under this mechanism and is focused on infrastructure development rather than a clinical trial.
Are clinical trials allowed under this opportunity?
No. The opportunity is explicitly labeled Clinical Trial Not Allowed. Applicants should plan for infrastructure development and related research activities that do not meet NIH’s definition of a clinical trial, rather than proposing an interventional clinical trial.
What is the program trying to enable in the long run?
The program aims to catalyze integrated and expanded research that better reflects real-world diversity and enables innovative future studies. The overall goal is to create a durable platform for equitable and more precise AD/ADRD research by making it easier to recruit, characterize, and follow understudied populations using richer, multidimensional data.
Who is eligible to apply?
The opportunity lists a broad set of eligible U.S.-based applicants, including many government, academic, nonprofit, and private-sector organizations, as well as community and faith-based organizations and other entities. Eligibility is intentionally broad to support partnerships that connect academic expertise with trusted community presence and culturally grounded engagement.
What types of government entities are eligible?
Eligible applicants include government entities such as:
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public housing authorities / Indian housing authorities
- U.S. territories or possessions
Are colleges and universities eligible?
Yes. Eligible applicants include public and state-controlled institutions of higher education and private institutions of higher education. The listing also calls out multiple categories of institutions that are often closely connected to minority health and disparities work.
Which minority-serving or mission-driven institutions are specifically called out?
The announcement specifically mentions eligibility for (among others):
- Historically Black Colleges and Universities (HBCUs)
- Hispanic-serving Institutions
- Tribally Controlled Colleges and Universities (TCCUs)
- Alaska Native and Native Hawaiian Serving Institutions
- Asian American Native American Pacific Islander Serving Institutions (AANAPISISs)
Are tribal entities eligible?
Yes. Eligible applicants include federally recognized Native American tribal governments and also tribal organizations other than federally recognized tribal governments. The listing also notes eligibility for tribal governments other than federally recognized ones.
Can nonprofits apply?
Yes. The opportunity allows nonprofits with 501(c)(3) status and nonprofits without 501(c)(3) status.
Can for-profit organizations apply?
Yes. The eligibility list includes for-profit organizations other than small businesses and also includes small businesses.
Are faith-based and community-based organizations eligible?
Yes. The announcement explicitly includes faith-based or community-based organizations as eligible applicants, supporting the program’s focus on trusted partnerships and community-engaged capacity building.
Are non-U.S. (foreign) organizations allowed to apply?
No. Non-domestic (non-U.S.) entities and foreign institutions are not eligible to apply under this opportunity.
Can a U.S. organization include a non-domestic component?
No. The listing states that non-domestic components of U.S. organizations are not eligible.
Are foreign components allowed in any form?
No. The opportunity states that foreign components (as NIH defines them in the NIH Grants Policy Statement) are not allowed. This means planned project activities and organizational participation must remain domestic under NIH rules.
What is the CFDA number for this opportunity?
The listing identifies this as a discretionary health funding opportunity under CFDA 93.866.
What is the award ceiling mentioned in the listing?
The provided information indicates an award ceiling of $350,000.
When was this opportunity created, and what closing date is listed?
The listing states the opportunity was created on August 8, 2022, and the original closing date is listed as October 21, 2022.
Does the provided information state how many awards will be made?
No. The text provided does not specify the exact number of expected awards, but it describes an intent to seed multiple collaborative efforts that collectively strengthen the field’s capacity for precision medicine research addressing minority health and disparities in AD/ADRD.
What is the overall takeaway for applicants designing a project?
The opportunity is best understood as an infrastructure-building push. A competitive approach, based on the description provided, would focus on creating durable resources and collaborative frameworks (including integrated datasets and community-engaged capacity) that enable more equitable, more precise AD/ADRD research over time, while staying within the “Clinical Trial Not Allowed” boundary.
Browse more opportunities from the same category: Health
Next opportunity: Maternal Health Research Centers of Excellence Data Innovation and Coordinating Hub/Resource Center (U24 Clinical Trial Not Allowed)
Previous opportunity: Early-Stage Therapy Development for ADRD (R61/R33 Clinical Trial Not Allowed)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AG 23 020
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AG 23 020) also looked into and applied for these:
| Funding Opportunity |
|---|
| REsearch Across Complementary and Integrative Health Institutions (REACH) Virtual Resource Centers (U24 Clinical Trial Not Allowed) Apply for RFA AT 23 004 Funding Number: RFA AT 23 004 Agency: National Institutes of Health Category: Health Funding Amount: $750,000 |
| AHRQ Mentored Clinical Scientist Research Career Development Award (K08) Apply for PA 22 232 Funding Number: PA 22 232 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| Identifying Host Cell Death Pathway Targets for Host-Directed Therapies for Treatment of Mtb and Mtb/HIV Co-Infection (R01 Clinical Trial Not Allowed) Apply for PAR 22 223 Funding Number: PAR 22 223 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Transplantation Statistical and Clinical Coordinating Center (T-SCCC) (U01 Clinical Trial Not Allowed) Apply for RFA AI 22 057 Funding Number: RFA AI 22 057 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIAMS Clinical Trial Planning Grant (R34) - Clinical Trial Not Allowed Apply for PAR 22 205 Funding Number: PAR 22 205 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Molecular Phenotypes of Null Alleles in Cells (MorPhiC) Phase I: Data Analysis and Validation Centers (U01 Clinical trials not allowed) Apply for RFA HG 22 019 Funding Number: RFA HG 22 019 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| Advancing Health and Malaria Services Apply for 72068522RFA00001 Funding Number: 72068522RFA00001 Agency: Senegal USAID-Dakar Category: Health Funding Amount: $39,500,000 |
| AD/ADRD, Adverse Childhood Experiences, and Social Determinants of Health Ancillary Studies of Existing Longitudinal Cohorts (R01 - Clinical Trial Not Allowed) Apply for PAR 22 221 Funding Number: PAR 22 221 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Javits Neuroscience Investigator Award Extension Request (Type 4 Clinical Trial Optional) Apply for PAR 23 022 Funding Number: PAR 23 022 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Integrative Research to Understand the Impact of Sex Differences on the Molecular Determinants of AD Risk and Responsiveness to Treatment (U01 Clinical Trial Optional) Apply for PAR 22 228 Funding Number: PAR 22 228 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Fostering Mental, Emotional, and Behavioral (MEB) Health Among Children in School Settings: Opportunities for Multisite Trials of Complementary and Integrative Health Interventions (Clinical Trial Optional) Apply for RFA AT 23 003 Funding Number: RFA AT 23 003 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Research Resource Center to Build an Open-Access Repository and Database for Anatomical and Physiological Correlates of Acupoints (U24, Clinical Trial Optional) Apply for RFA AT 23 005 Funding Number: RFA AT 23 005 Agency: National Institutes of Health Category: Health Funding Amount: $700,000 |
| FY 2023 AmeriCorps State and National Public Health AmeriCorps Grants Apply for AC 08 20 22 Funding Number: AC 08 20 22 Agency: AmeriCorps Category: Health Funding Amount: Case Dependent |
| Practice-Based Research Integrating Multidisciplinary Experiences in Dental Schools (PRIMED) (U01 Clinical Trial Not Allowed) Apply for RFA DE 23 012 Funding Number: RFA DE 23 012 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| AHRQ Conference Grant Programs (R13) Apply for PA 22 238 Funding Number: PA 22 238 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $50,000 |
| Maintaining Immunity after Immunization (U01 Clinical Trial Not Allowed) Apply for RFA AI 22 055 Funding Number: RFA AI 22 055 Agency: National Institutes of Health Category: Health Funding Amount: $450,000 |
| REsearch Across Complementary and Integrative Health Institutions (REACH) Virtual Resource Centers (U24 Clinical Trial Not Allowed) Apply for RFA AT 23 007 Funding Number: RFA AT 23 007 Agency: National Institutes of Health Category: Health Funding Amount: $750,000 |
| Optimization of Genome Editing Therapeutics for Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD) (U01 - Clinical Trials Not Allowed) Apply for RFA NS 23 017 Funding Number: RFA NS 23 017 Agency: National Institutes of Health Category: Health Funding Amount: $650,000 |
| NIA Research and Entrepreneurial Development Immersion (REDI): Entrepreneurship Enhancement Award (R25 Independent Clinical Trial Not Allowed) Apply for PAR 22 226 Funding Number: PAR 22 226 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| NIA Research and Entrepreneurial Development Immersion (REDI): Mentored Entrepreneurial Career Development Award (K01 Clinical Trial Not Allowed) Apply for PAR 22 227 Funding Number: PAR 22 227 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AG 23 020", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.